 RADNOR, Pa., July 22, 2021 PRNewswire -- NRx Pharmaceuticals NRx Nasdaq: NRXP announced today it has validated the first commercial formulation of ZYESAMITM aviptadil for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropriate storage conditions. 